Speech-Language Pathologists in Amesbury, MA Accepting Medicare

8 Speech-Language Pathologists found. Showing 1 - 8

Maripaul Mcginn, SLP.CCC Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 110 Haverhill Rd, Amesbury, MA 01913 Phone: 978-609-4007

Jolene Cairns Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 110 Haverhill Rd Ste 101, Amesbury, MA 01913 Phone: 855-390-7774    Fax: 855-734-4666

Jason Curtis Speech-Language Pathologist Medicare: Accepting Medicare Assignments Practice Location: 110 Haverhill Rd Ste 101, Amesbury, MA 01913 Phone: 855-390-7774    Fax: 855-734-4666

Heather Currier Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 5 Birch Ln, Amesbury, MA 01913 Phone: 303-868-5995

Ms. Molly Suzanne Mitchell, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 6 Morrill Pl, Amesbury, MA 01913 Phone: 978-388-3500

Sally Paulding, MS CCC SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 6 Morrill Pl, Amesbury, MA 01913 Phone: 978-388-3500

Mollie Gwinn, M.S., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 78 Monroe St, Amesbury, MA 01913 Phone: 978-270-6020

Mrs. Angela Elizabeth Tortola, MS. CCC SLP Speech-Language Pathologist Medicare: Accepting Medicare Assignments Practice Location: 110 Haverhill Rd, Ste 101, Amesbury, MA 01913 Phone: 978-378-3358

News Archive

Nepalese Rhesus monkeys may provide new alternative for HIV/AIDS research

Rhesus monkeys in Nepal may provide a suitable alternative to alleviate a critical shortage of laboratory animals used in work to develop vaccines against diseases such as HIV/AIDS.

European countries to review impact of environmental policies on popluation health status

Representatives of 53 Member States from the WHO European Region will gather in Parma, Italy, on 10-12 March 2010 to review the impact of national and cross-border environmental policies on the health status of their populations.

First long-acting injectable HIV treatment appraised and approved by NICE

ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc, with Pfizer Inc. and Shionogi Limited as shareholders, is pleased to announce that eligible people living with Human Immunodeficiency Virus (HIV) in England and Wales will soon have routine access to Vocabria (cabotegravir long-acting injection) developed by ViiV Healthcare in combination with Rekambys (rilpivirine long-acting injection), developed by Janssen Sciences Ireland UC (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Biovest announces new data from BiovaxID Phase II mantle cell lymphoma trial

Biovest International, Inc., a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc., today announced that an abstract reporting new data from the BiovaxID Phase II mantle cell lymphoma clinical trial conducted by the U.S. National Cancer Institute (NCI) is now available on-line with the significance of these results to be presented by the NCI at the 2012 American Society of Clinical Oncology Annual Meeting.

AmerisourceBergen increases quarterly dividend 25% to $0.10 per common share

The Board of Directors of AmerisourceBergen Corporation today increased the Company's quarterly dividend rate 25 percent to $0.10 per common share from $0.08 per common share.

Read more Medical News

› Verified 7 days ago